Tianjin Haihe Hospital
Welcome,         Profile    Billing    Logout  
 39 Trials 
64 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Du, Juan
NCT06476210: The Safety and Efficacy of BDL(Bedaquiline Plus Delamanid Plus Linezolid) Regimen in Subjects With Pulmonary Infection of Multi-drug Resistant Tuberculosis (MDR-TB) or Rifampicin-Resistant Tuberculosis (RR-TB)

Recruiting
4
45
RoW
BDL regimen
Beijing Chest Hospital, Public Health Clinical Medical Center of Chengdu, Wuhan Institute for Tuberculosis Control, Changsha Central Hospital, Anhui Chest Hospital, Hunan Chest Hospital, Shandong Public Health Clinical Center
Pulmonary Tuberculosis
06/25
06/26
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)

Active, not recruiting
4
8250
RoW
Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy
Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases
04/25
04/25
PROSPECT, NCT05306223: A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China

Recruiting
4
212
RoW
Bedaquiline, SIRTURO, Levofloxacin, Linezolid, Cycloserine, Clofazimine, Pyrazinamide, Protionamide
Beijing Chest Hospital
Tuberculosis, Multidrug-Resistant
08/25
08/25
NCT04300114: A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

Terminated
3
5
RoW
Fluzoparib, SHR3162, Placebo
Jiangsu HengRui Medicine Co., Ltd.
Metastatic Pancreatic Cancer
02/22
02/22
INSPIRE-BDLL, NCT06649721: Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort

Not yet recruiting
3
120
RoW
bedaquiline, BDQ, B, delamanid, DLM, D, linezolid, LZD, L, Levofloxacin, LFX, Clofazimine, CFZ, C
Huashan Hospital, Beijing Chest Hospital
Drug-resistant Tuberculosis, Pulmonary Tuberculosis, Rifampin-resistant Tuberculosis
06/27
06/27
INSPIRE-CODA, NCT06081361: Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort

Recruiting
3
186
RoW
Bedaquiline, BDQ, Delamanid, DLM, Contezolid, CZD, Levofloxacin, LFX, Moxifloxacin, MFX, Clofazimine, CFZ, Linezolid, LZD, Cycloserine, CS, Prothionamide, Pto, Pyrazinamide, PZA, Para-Aminosalicylic Acid, PAS, Ethambutol, EMB
Beijing Chest Hospital, National Medical Center for Infectious Diseases
Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
10/26
12/26
NCT05634564: Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic Cancer

Recruiting
2
62
RoW
Tislelizumab, Gemcitabine, Nab paclitaxel, Hypofractionated radiotherapy with simultaneous integrated boost
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Pancreatic Carcinoma
04/23
12/23
NCT06305104: Clinical Trial to Explore the Skin Test Dosage of EEC in People Aged 18 to 65 Years Old and the Safety and Preliminary Efficacy in People Aged 3 to 75 Years Old.

Recruiting
2
420
RoW
2.5μg/ml EEC, 5μg/ml EEC, 5 unit（U） EC
Chengdu CoenBiotech Co., Ltd, Beijing Chest Hospital, Capital Medical University, Wuhan Institute for Tuberculosis Control, The Public Health Clinical Center of Chengdu, Xuzhou Infectious Disease Hospital, Jiangsu Province Centers for Disease Control and Prevention, Changde First People's Hospital
Tuberculosis
05/24
06/24
NCT06389760: Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer

Recruiting
2
57
RoW
Nimotuzumab, Taixinsheng, mFOLFIRINOX, GX
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Pancreatic Cancer
09/26
09/26
NCT06224036: Clinical Study of JDB0131 Benzenesulfonate Tablets in Patients With Drug-sensitive Pulmonary Tuberculosis

Recruiting
2
52
RoW
JDB0131, Delamanid, Ethylpyrazine rifampicide (II)
Beijing Chest Hospital, West China Hospital, Wuhan Pulmonary Hospital (Wuhan Institute For Tuberculosis Control)
Drug-resistant Tuberculosis
03/24
03/24
PAAG, NCT05493995: A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer.

Completed
2
66
RoW
Penpulimab, AK105, Anlotinib, Nab paclitaxel, Gemcitabine
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Pancreatic Neoplasms
05/24
05/24
CZ-WM01, NCT05979948: A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia

Recruiting
2
60
RoW
Zanubrutinib, Bendamustine, Rituximab
Shanghai Changzheng Hospital, RenJi Hospital, Huashan Hospital, Shanghai 6th People's Hospital, Huadong Hospital
Waldenström's Macroglobulinemia
04/25
12/25
RCT-PAAG, NCT06051851: Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer

Recruiting
2
177
RoW
Penpulimab, Anlotinib, Nab paclitaxel, Gemcitabine
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Pancreatic Adenocarcinoma Metastatic
07/25
07/26
NCT05594797: Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM

Recruiting
2
100
RoW
Human BCMA Targeted T Cells Injection, BCMA CAR-T
Hrain Biotechnology Co., Ltd., Shanghai Changzheng Hospital, First Affiliated Hospital of Wenzhou Medical University
Multiple Myeloma
07/25
07/27
NCT04941937: Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM

Recruiting
2
90
RoW
Selinexor, ATG-010/KPT-330, Thalidomide, fǎn yìng tíng, Lenalidomide, Revlimid, An xian, Pomalidomide, POMALYST, Dexamethasone, Dex
Juan Du
Multiple Myeloma
12/25
12/25
GC012F-32, NCT04935580: Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients

Recruiting
1/2
20
RoW
GC012F injection
Shanghai Changzheng Hospital, Gracell Biotechnology Shanghai Co., Ltd.
Multiple Myeloma
07/23
07/23
NCT06235229: A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma

Recruiting
1/2
110
RoW
GC012F
Gracell Biotechnologies Ltd.
Multiple Myeloma
03/26
06/26
NCT05302648: To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM

Active, not recruiting
1
18
RoW
Human Derived anti-BCMA CAR-T Injection, BCMA CAR-T
Hrain Biotechnology Co., Ltd., Shanghai Changzheng Hospital
Multiple Myeloma
12/24
12/25
CIBI343A101, NCT05458219: A First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors

Recruiting
1
470
US, RoW
IBI343
Innovent Biologics (Suzhou) Co. Ltd., Innovent Biologics, Inc., TigerMed
Locally Advanced Unresectable or Metastatic Solid Tumors
12/25
12/25
NCT05412329: Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma

Recruiting
1
9
RoW
GC012F injection
Shanghai Changzheng Hospital, Gracell Biotechnology Shanghai Co., Ltd.
Multiple Myeloma
06/24
06/24
NCT06407947: Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma

Recruiting
1
10
RoW
Chimeric antigen receptor modified T cells Infusion, Single Group Assignment
Shanghai Changzheng Hospital, CARsgen Therapeutics Co., Ltd.
Multiple Myeloma
06/27
06/27
CT071-CG7001, NCT05838131: Study of CT071 Injection in RRMM or PPCL

Active, not recruiting
1
20
RoW
Experimental: CAR-T cells Infusion, Single Group Assignment
Shanghai Changzheng Hospital, CARsgen Therapeutics Co., Ltd.
Multiple Myeloma, Primary Plasma Cell Leukemia
07/25
07/25
NCT06718270: a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia

Recruiting
1
24
RoW
CAR-T cells Infusion
Shanghai Changzheng Hospital, CARsgen Therapeutics Co., Ltd.
Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory Plasma Cell Leukemia
01/27
12/27
NCT05840107: Study of FasT CAR-T GC012F Injection NDMM Patients

Recruiting
1
18
RoW
GC012F injection
Shanghai Changzheng Hospital, Gracell Biotechnology Shanghai Co., Ltd.
Multiple Myeloma
09/25
09/25
NCT06045091: To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL

Recruiting
1
18
RoW
Human BCMA targeted CAR-NK cells injection, BCMA CAR-NK
Hrain Biotechnology Co., Ltd., Shanghai Changzheng Hospital
Multiple Myeloma, Plasma Cell Leukemia
09/25
09/27
NCT04122092: Evaluation of Ultrasensitive Chromosomal Aneuploidy Detection for Detecting Minimal Residual Disease in Multiple Myeloma

Recruiting
N/A
100
RoW
The level of plasma cfDNA CINs
Shanghai Changzheng Hospital
Multiple Myeloma
10/21
10/22
NCT06494514: NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer

Recruiting
N/A
40
RoW
nal-IRI+Oxaliplatin+5-FU/LV+PD-1, Gemcitabine + albumin-paclitaxel+PD-1
Du Juan
Locally Advanced Pancreatic Cancer
04/27
04/27
Zhang, Wenhong
HS-10234-401, NCT06743438: Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With CHB

Active, not recruiting
4
640
RoW
Tenofovir Amibufenamide（TMF）, HS-10234
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Hepatitis B, Chronic
06/24
09/29
TB-TRUST, NCT03867136: Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)

Completed
4
354
RoW
PZA sensitivity guided ultra-short all Oral Regimen, Standardized Shorter Regimen
Huashan Hospital
Multidrug Resistant Tuberculosis
08/24
08/24
NCT04201808: Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides

Recruiting
4
100
RoW
Tenofovir Alafenamide 25 MG, Vemlidy
New Discovery LLC, Beijing Ditan Hospital
Hepatitis B, Chronic
09/23
09/23
SWIFT, NCT06153069: Subclinical TB With Innovative Modified Short-course Regimens

Active, not recruiting
4
556
RoW
Short-course regimen, Standard regimen
Huashan Hospital
Tuberculosis
10/25
11/27
NCT05279235: Efficacy and Safety of JT001 (VV116) Compared With Favipiravir

Terminated
3
290
RoW
JT001, VV116, JT001 placebo, VV116 placebo, Favipiravir, Favipiravir placebo
Shanghai Vinnerna Biosciences Co., Ltd., Sponsor GmbH
Moderate to Severe COVID-19
12/22
12/22
CURE-SepSIRS, NCT05391789: Clinical Efficacy of Ulinastatin for Treatment of Sepsis With Systemic Inflammatory Response Syndrome

Not yet recruiting
3
120
RoW
Ulinastatin, Treatment, Placebo, Control
Huashan Hospital
Sepsis
06/23
12/23
ZX-7101A-207, NCT06099873: Study to Assess the Safety and Efficacy of ZX-7101A in Adolescents with Influenza

Recruiting
3
360
RoW
ZX-7101A, Placebo
Nanjing Zenshine Pharmaceuticals
Respiratory Viral Infection
01/25
03/25
TB-YOUTH, NCT06022146: TB YOUTH - TB sYstemic Management Using One-month, Ultra-short TPT Regimen for scHool Contacts

Recruiting
3
3520
RoW
Rifampin and Isoniazid, isoniazid and rifapentine
Huashan Hospital
Tuberculosis, Latent Tuberculosis
09/26
09/26
INSPIRE-CODA, NCT06081361: Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort

Recruiting
3
186
RoW
Bedaquiline, BDQ, Delamanid, DLM, Contezolid, CZD, Levofloxacin, LFX, Moxifloxacin, MFX, Clofazimine, CFZ, Linezolid, LZD, Cycloserine, CS, Prothionamide, Pto, Pyrazinamide, PZA, Para-Aminosalicylic Acid, PAS, Ethambutol, EMB
Beijing Chest Hospital, National Medical Center for Infectious Diseases
Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
10/26
12/26
NCT05242042: JT001 (VV116) for the Early Treatment of COVID-19

Terminated
2/3
381
RoW
JT001, VV116, Placebo
Shanghai JunTop Biosciences Co., LTD, Sponsor GmbH
Mild to Moderate COVID-19
03/23
03/23
ORIENT, NCT05401071: Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T)

Recruiting
2/3
2442
RoW
Short Regimen with Rifapentine 10mg/kg, Standardized Regimen, Short Regimen with Rifapentine 15mg/kg, Short Regimen with Rifapentine 20mg/kg
Huashan Hospital
Tuberculosis, Pulmonary
10/24
11/27
NCT05445934: Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study)

Recruiting
2/3
1188
RoW
FB2001, DC402234, FB2001 placebo
Frontier Biotechnologies Inc.
COVID-19
11/23
12/23
B-UNITED, NCT06537414: A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

Recruiting
2
280
Europe, Canada, Japan, US, RoW
Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo
GlaxoSmithKline
Chronic Hepatitis B Virus Infection, Hepatitis B
10/27
10/27
NCT05217732: Study to Assess the Safety, Tolerability and Pharmacokinetics of ZX-7101A and the Food Effect in Healthy Volunteers

Completed
1
66
RoW
ZX-7101A, Placebo
Nanjing Zenshine Pharmaceuticals
Safety Issues, Tolerance, Pharmacokinetics, Food Effect
08/22
12/22
NCT04883177: Effectiveness and Safety of the COVID-19 Vaccination for Patients With Liver Disease (CHESS2101)

Completed
N/A
1000
RoW
Hepatopancreatobiliary Surgery Institute of Gansu Province, LanZhou University, Huashan Hospital, The Sixth People's Hospital of Shenyang City, Xingtai City People's Hospital, Jinchang Central Hospital, Baoding People's Hospital, The Third People's Hospital of Zhenjiang City, Shanxi Bethune Hospital, Wuhan Jinyintan Hospital, Jincheng People's Hospital, The Third People's Hospital of Tibet Autonomous Region, People's Hospital of Ningxia Hui Autonomous Region, Fuling Central Hospital of Chongqing City, Hospital of the Chengdu Office of the People's Government of Tibet Autonomous Region, The Central Hospital of Lishui City, The Third People's Hospital of Linfen City, Yibin First People's Hospital, Jingzhou Central Hospital, Wuxi Fifth People's Hospital, Qingyang People's Hospital, The First Affiliated Hospital of Anhui Medical University, Beilun Hospital of Traditional Chinese Medicine, Henan Provincial People's Hospital, Qingdao Sixth People's Hospital, The First Affiliated Hospital of Xiamen University, Shandong Provincial Hospital, Beijing YouAn Hospital, The First People's Hospital of Taicang, The Third People's Hospital of Taiyuan, Tianjin Second People's Hospital, Tianjin Third Central Hospital, Qishan Hospital of Yantai City, Affiliated Hospital of Yunnan University, The First People's Hospital of Yunnan, The Fourth Affiliated Hospital of Zhejiang University, Third Affiliated Hospital, Sun Yat-Sen University, First Affiliated Hospital of Chongqing Medical University
COVID-19, Liver Disease, Vaccine Reaction
01/22
05/22
AI-MIRID, NCT06553911: Exploring the Application Efficacy of Artificial Intelligence (AI) Diagnostic Tools in Medical Imaging (MI) of Respiratory(R) Infectious (I) Disease (D)

Recruiting
N/A
2000
RoW
Artificial Intelligence-based medical imaging interpretation
Huashan Hospital
Respiratory Infectious Diseases, Artificial Intelligence, Medical Imaging
12/25
12/26
NMCIDCHESS2201, NCT05204602: Safety and Immunogenicity of COVID-19 Vaccine Booster in Patients With Liver Diseases

Recruiting
N/A
1000
RoW
Huashan Hospital, LanZhou University, Xingtai People's Hospital, The Third Central Hospital of Tianjin, The Third People's Hospital of Taiyuan, Lishui Country People's Hospital, Baoding People's Hospital, The Affiliated Hospital of Qingdao University, Nanjing Hospital of Chinese Medicine affiliated to Nanjing University of Chinese Medicine, The Fifth People's Hospital of Wuxi, Jincheng People's Hospital, The Sixth Peoples Hospital of Shenyang, Zhenjiang Third Hospital, The Third People's Hospital of Linfen City, The First Affiliated Hospital of Dalian Medical University, The Fourth People's Hospital of Qinghai Province, The Third People's Hospital of Tibet Autonomous Region, The Second Affiliated Hospital of Chongqing Medical University, Peking University Health Science Center, The Affiliated Hospital Of Southwest Medical University
COVID-19, Vaccine Reaction, Liver Diseases
08/22
12/22
TB-TRUSTplus, NCT04717908: Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS

Completed
N/A
89
RoW
Bedaquiline, BDQ, Pyrazinamide, PZA, Linezolid, LZD, Cycloserine, Cs, Clofazimine, CFZ
Huashan Hospital
Multidrug Resistant Tuberculosis
06/24
06/24
STAT, NCT05906459: Simplification and Test and Treat Strategies Towards Hepatitis C Eliminationplatform" in China

Recruiting
N/A
20000
RoW
Anti-HCV antibody and HCV core antigen testing
Huashan Hospital
Hepatitis C Virus Infection
12/23
06/24
NCT05855395: The Standard of Care Combined With Glucocorticoid in Elderly People With Mild or Moderate COVID-19

Recruiting
N/A
5815
RoW
Glucocorticoid, dexamethasone, prednisone, methylprednisolone
Huashan Hospital
COVID-19
05/24
12/24
NCT04020536: Real World Study of Classic Infectious Disease

Recruiting
N/A
10000
RoW
Antibiotics
Huashan Hospital, First Affiliated Hospital of Xinjiang Medical University, First Affiliated Hospital of Harbin Medical University, The ninth Hospital of NanChang city, Luoyang Central Hospital, Second Affiliated Hospital of Nanchang University, The Fifth Affiliated Hospital Xinjiang Medical University, LanZhou University, Huizhou Municipal Central Hospital, First Affiliated Hospital of Fujian Medical University, Fuzhou Municipal Infectious Diseases Hospital, Henan Provincial People's Hospital, The First Affiliated Hospital of Lanzhou Medical University, Linyi People's Hospital, Nantong University, Nanyang Central Hospital, Qilu Hospital of Shandong University, Qianfoshan Hospital, Infectious Hospital of Jining City, The Affiliated Hospital of Jining Medical University and Zaozhuang City, The First Affiliated Hospital of Shanxi Medical University, First Affiliated Hospital Xi'an Jiaotong University, People's Hospital of Xinjiang Uygur Autonomous Region, Yuncheng Central Hospital, Zibo Central Hospital, The Second Affiliated Hospital of Henan Medical University, West Hospital of the First Affiliated Hospital of Guangxi University, First Affiliated Hospital of Jilin University, The Affiliated Hospital of Xuzhou Medical University, The First Affiliated Hospital with Nanjing Medical University, The First Affiliated Hospital of Anhui Medical University, The Second Hospital of Shandong University, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Brucelloses, Epidemic Hemorrhagic Fever, Kala-Azar
06/24
06/29
NCT04025944: Real World Study of Chronic Viral Hepatitis

Recruiting
N/A
10000
RoW
Huashan Hospital
Hepatitis, Chronic
08/24
08/29
GRACE-TB, NCT03604848: NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB

Not yet recruiting
N/A
488
RoW
WHO-approved MDR-TB regimen, NGS-guided regimen: Regimen A, NGS-guided regimen: Regimen B, NGS-guided regimen: Regimen C
Huashan Hospital
Multidrug Resistant Tuberculosis
08/24
08/24
ESAR, NCT04955756: Early Identification and Severity Prediction of Acute Respiratory Infectious Disease

Recruiting
N/A
440
RoW
mNGS, Multiplex PCR
Huashan Hospital
Acute Respiratory Infection, Severe Pneumonia, Next Generation Sequencing, Multiplex PCR
12/24
12/24
NCT05912010: A Study on Pathogenic Surveillance and Nasopharyngeal Carriage of Children and Adolescents Based on Hospitals and Communities in Hainan Province

Recruiting
N/A
6000
RoW
NP/OP swab
Huashan Hospital
Pneumonia
12/24
12/24
NCT06033807: Active Screening of Latent Tuberculosis Infection in School Contacts of Active Tuberculosis Patients

Recruiting
N/A
31440
RoW
QuantiFERON-TB Gold (QFT) test, Chest CT Scan, Chest X-ray Scan, Sputum Culture, Sputum Xpert MTB/RIF
Huashan Hospital, Guizhou Center for Disease Control and Prevention
Tuberculosis, Latent Tuberculosis Infection
09/25
12/25
INSPIRE-TB, NCT05081401: Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis

Recruiting
N/A
3000
RoW
This is a non-intervention observational study.
Huashan Hospital
Multidrug Resistant Tuberculosis
12/25
12/25
NCT05937178: Real-world Study Optimizing Nucleotide-analogues

Recruiting
N/A
20000
RoW
ETV/TAF/TDF/TMF/IFN, ETV/TAF/TDF/TMF
Huashan Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, Beijing YouAn Hospital, Peking University People's Hospital, Peking University First Hospital, Xiamen Hospital of Traditional Chinese Medicine, First Affiliated Hospital of Fujian Medical University, LanZhou University, Third Affiliated Hospital, Sun Yat-Sen University, First Affiliated Hospital of Guangxi Medical University, The Affiliated Hospital Of Guizhou Medical University, Hainan General Hospital, Hebei Medical University Third Hospital, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Henan Provincial People's Hospital, The Second Affiliated Hospital of Harbin Medical University, Tongji Hospital, Wuhan Union Hospital, China, Renmin Hospital of Wuhan University, Central South University, Xiangya Hospital of Central South University, The First Hospital of Jilin University, the Second Hospital of Nangjing, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Hospital of Xuzhou Medical University, The First Affiliated Hospital of Nanchang University, Shengjing Hospital, Qingdao Sixth People's Hospital, Shandong Provincial Hospital Affiliated to Shandong First Medical University, The Second Hospital of Shandong University, The First Affiliated Hospital of Shanxi Medical University, Tang-Du Hospital, First Affiliated Hospital Xi'an Jiaotong University, Ruijin Hospital, West China Hospital, Tianjin Second People's Hospital, First Affiliated Hospital of Xinjiang Medical University, The First People's Hospital of Yunnan, Shulan (Hangzhou) Hospital, Zhejiang University, Southwest Hospital, China, The Second Affiliated Hospital of Chongqing Medical University, Sichuan Provincial People's Hospital
Hepatitis B, Chronic
01/29
01/29
NCT05965388: Predictive Value of HBV pgRNA on Long-term Outcomes in Hepatitis B Patients Treated With Antiviral Therapy

Not yet recruiting
N/A
5000
RoW
nucleoside analogues or interferon
Wen-hong Zhang, Shandong Provincial Hospital Affiliated to Shandong First Medical University, First Affiliated Hospital Xi'an Jiaotong University, The Affiliated Hospital of Xuzhou Medical University, First Affiliated Hospital of Fujian Medical University, The Third People's Hospital of Taiyuan, The First People's Hospital of Yunnan, The First Affiliated Hospital of Anhui Medical University, Wuhan Union Hospital, China, The First Affiliated Hospital with Nanjing Medical University
HBV, HCC
02/29
02/29
TCCT, NCT04484129: MDR-TB Close Contacts Tracing in China ( Study)

Not yet recruiting
N/A
500
RoW
Huashan Hospital
Multidrug Resistant Tuberculosis
12/22
12/22
NCT05493917: A Real-world Study to Evaluate the Safety and Immunogenicity of a Third-dose Booster After Two Doses of an Inactivated COVID-19 Vaccine

Recruiting
N/A
2000
RoW
an inactivated SARS-CoV-2 vaccine named BBIBP-CorV
Huashan Hospital
COVID-19, Vaccine Reaction
12/22
12/22
OASIS, NCT04896255: Long-term Outcomes of Anti-viral Therapies in Patients With Chronic Viral Hepatitis B

Recruiting
N/A
20000
RoW
peginterferon alpha based regimen, nucleos(t)ide
Huashan Hospital, Chinese Foundation for Hepatitis Prevention and Control, Taiyuan No.3 Hospital, First Affiliated Hospital of Chongqing Medical University, Beijing YouAn Hospital, Henan Provincial People's Hospital, Yunnan Provincial No.1 Hospital, Third Affiliated Hospital, Sun Yat-Sen University, The First Affiliated Hospital of Anhui Medical University, The First Affiliated Hospital of Xiamen University, Beijing Ditan Hospital, Tianjing No.2 People's Hospital, Qingdao No.6 People's Hospital, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Ningbo Beilun District Traditional Chinese Medicine Hospital, Wuxi No.5 People's Hospital, Taicang No.1 People's hospital, First Affiliated Hospital Xi'an Jiaotong University
Chronic Hepatitis b
07/25
07/30
Pei, Yi
NCT06476210: The Safety and Efficacy of BDL(Bedaquiline Plus Delamanid Plus Linezolid) Regimen in Subjects With Pulmonary Infection of Multi-drug Resistant Tuberculosis (MDR-TB) or Rifampicin-Resistant Tuberculosis (RR-TB)

Recruiting
4
45
RoW
BDL regimen
Beijing Chest Hospital, Public Health Clinical Medical Center of Chengdu, Wuhan Institute for Tuberculosis Control, Changsha Central Hospital, Anhui Chest Hospital, Hunan Chest Hospital, Shandong Public Health Clinical Center
Pulmonary Tuberculosis
06/25
06/26
PROSPECT, NCT05306223: A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China

Recruiting
4
212
RoW
Bedaquiline, SIRTURO, Levofloxacin, Linezolid, Cycloserine, Clofazimine, Pyrazinamide, Protionamide
Beijing Chest Hospital
Tuberculosis, Multidrug-Resistant
08/25
08/25
INSPIRE-BDLL, NCT06649721: Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort

Not yet recruiting
3
120
RoW
bedaquiline, BDQ, B, delamanid, DLM, D, linezolid, LZD, L, Levofloxacin, LFX, Clofazimine, CFZ, C
Huashan Hospital, Beijing Chest Hospital
Drug-resistant Tuberculosis, Pulmonary Tuberculosis, Rifampin-resistant Tuberculosis
06/27
06/27
INSPIRE-CODA, NCT06081361: Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort

Recruiting
3
186
RoW
Bedaquiline, BDQ, Delamanid, DLM, Contezolid, CZD, Levofloxacin, LFX, Moxifloxacin, MFX, Clofazimine, CFZ, Linezolid, LZD, Cycloserine, CS, Prothionamide, Pto, Pyrazinamide, PZA, Para-Aminosalicylic Acid, PAS, Ethambutol, EMB
Beijing Chest Hospital, National Medical Center for Infectious Diseases
Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
10/26
12/26
NCT06525272: A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of OsrhCT in Patients With Pleurisy

Not yet recruiting
1
72
RoW
Recombinant Human Chymotrypsin(OsrhCT), Freeze-dried Powder of Recombinant Human Chymotrypsin(OsrhCT), Placebo for Recombinant Human Chymotrypsin(OsrhCT), Freeze-dried Powder of Placebo for Recombinant Human Chymotrypsin(OsrhCT)
Healthgen Biotechnology Corp.
Pleurisy
07/25
12/25

Download Options